Literature DB >> 21499282

Denosumab in bone-metastatic prostate cancer: known effects on skeletal-related events but unknown effects on quality of life.

Oliver Sartor1.   

Abstract

Entities:  

Year:  2011        PMID： 21499282      PMCID： PMC3739605          DOI： 10.1038/aja.2011.33

Source DB:  PubMed          Journal:  Asian J Androl        ISSN： 1008-682X            Impact factor:   3.285


× No keyword cloud information.
  2 in total

1.  Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study.

Authors:  Karim Fizazi; Michael Carducci; Matthew Smith; Ronaldo Damião; Janet Brown; Lawrence Karsh; Piotr Milecki; Neal Shore; Michael Rader; Huei Wang; Qi Jiang; Sylvia Tadros; Roger Dansey; Carsten Goessl
Journal:  Lancet       Date:  2011-02-25       Impact factor: 79.321

2.  A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma.

Authors:  Fred Saad; Donald M Gleason; Robin Murray; Simon Tchekmedyian; Peter Venner; Louis Lacombe; Joseph L Chin; Jeferson J Vinholes; J Allen Goas; Bee Chen
Journal:  J Natl Cancer Inst       Date:  2002-10-02       Impact factor: 13.506
  2 in total
  3 in total

Review 1.  Novel approaches in the pharmacotherapy of skeletal-related events in metastatic castrate-resistant prostate cancer.

Authors:  Shawn Spencer; Bernard L Marini; William D Figg
Journal:  Anticancer Res       Date:  2012-07       Impact factor: 2.480

Review 2.  Comparing cost-effectiveness analyses of denosumab versus zoledronic acid for the treatment of bone metastases.

Authors:  Kaitlin Koo; Kinsey Lam; Nicole Mittmann; Andre Konski; Kristopher Dennis; Liang Zeng; Henry Lam; Edward Chow
Journal:  Support Care Cancer       Date:  2013-03-22       Impact factor: 3.603

3.  A novel patient-derived intra-femoral xenograft model of bone metastatic prostate cancer that recapitulates mixed osteolytic and osteoblastic lesions.

Authors:  Omer Raheem; Anna A Kulidjian; Christina Wu; Young B Jeong; Tomonori Yamaguchi; Kristen M Smith; Daniel Goff; Heather Leu; Sheldon R Morris; Nicholas A Cacalano; Koichi Masuda; Catriona H M Jamieson; Christopher J Kane; Christina A M Jamieson
Journal:  J Transl Med       Date:  2011-10-28       Impact factor: 5.531
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.